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Health technology assessments imply evaluations of any 
type of approach or device, drug or medication that is in use 
or, as would be better, that is yet to be applied to healthcare. 
At present, there is some confusion between health technology 
assessments and the application of the original tools for evidence-
based medicine, to the point that the terms “evidence-based 
medicine” and “systematic reviews” were used as the descriptors 
(key words) in a recent article on the fundamentals of health 
technology assessments.1
Such evaluations in the light of reasonable evidence of ef-
fi cacy, effectiveness and safety evolve naturally to evaluations 
of the effi ciency of new technology (economic viability) and, 
furthermore, they also require assessment of the ethics of imple-
menting the subject of the assessment, whether it consists of 
diagnosis, screening, prevention, prophylaxis or therapy.
The ethical aspects are fundamental.2 For example, a kidney 
donated by an unrelated living individual may function as well as 
one from a related living donor, but this raises extremely impor-
tant ethical questions and requires regulation. The principle of 
non-harmfulness always needs to be taken into account, without 
forgetting about the patient’s right to make decisions regarding 
the likely risks and benefi ts of each possible alternative, after 
receiving appropriate information.
We physicians are becoming increasingly accustomed to 
obligatory assessments regarding the ethics of research proj-
ects, both of clinical and of experimental nature, conducted by 
research ethics committees within the institutions concerned 
and at the National Health Board (Conselho Nacional de Saúde). 
With regard to clinical trials, it is mandatory to obtain approval 
from the local ethics committee and to register the trial. We also 
take the view that it is of fundamental importance that, when 
the authorization for the research is granted, the researchers and 
the entities funding the project should take on an obligation to 
fulfi ll the commitment to publish the results from the clinical 
research. Through this, the promise made to patients who agree 
to participate in clinical studies after being convinced (by the 
researchers) that they will be running a calculated risk, with the 
purpose of contributing towards the improvement of scientifi c 
knowledge of use for humanity, can in fact be honored. Failure 
to publish is a failure to fulfi ll a tacit agreement with the par-
ticipants, which could be considered unethical. 
However, beyond this, with regard to producing syntheses of 
the technology assessments accomplished, after incorporating the 
evidence relating to effectiveness, effi ciency and safety, the new 
knowledge constitutes precious material to be integrated into 
the evidence-based clinical guidelines and will be tested like new 
products. The body of good evidence can then be incorporated 
into the guidelines. Since these guidelines are composed of com-
plex technology, a new technology assessment is thus required 
and, in our view, this should include establishing a rigorous 
consensus among the widest range of different professionals, 
specialists, funding providers, healthcare economists and patient 
representatives. Finally, there should be rigorous assessment of 
the ethical implications of applying the guideline. Through 
this, confl icts of interest and deleterious aspects of any type of 
corporatism can be reduced and decision-making can be more 
impartially centered on the fundamental human interests that 
are the motive for all the research accomplished. 
In summary, approval needs to be obtained not only for 
the bioethical aspects of clinical trials but also for those of 
technology assessments and clinical guidelines. Participation 
by specialists within the fi eld in question needs to form part of 
the consensus behind the corresponding guidelines, which will 
only achieve good professional adherence when they are based 
on good quality scientifi c evidence.
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